-
Mashup Score: 0
EHA Library; Pollyea D. May 18 2017; 180699;
Source: library.ehaweb.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1A RANDOMIZED CONTROLLED CLINICAL TRIAL DEMONSTRATES THAT PLASMA... by Carsten Müller-Tidow - 7 month(s) ago
EHA Library; Müller-Tidow C. Jun 10 2022; 357146;
Source: library.ehaweb.orgCategories: General Medicine News, Hem/OncsTweet-
RCT Plasma From Convalescent & Vaccinated Donors (#COVID19CP) Improves Outcome of #COVID19 Pts with Hematological Disease, Cancer or Immunosuppression [May 12, 2022] Carsten Müller-Tidow et al. Abst S282 #EHA2022 https://t.co/4TMiWXBPM0 #COVID19nCancer HT @DrJPHenderson https://t.co/N5R0lqeaJb
-
-
Mashup Score: 1GLOBAL RATES OF INFLUENZA (FV) AND PNEUMOCOCCAL (PV) VACCINATION IN... by Dr. Michael A. Thompson - 8 month(s) ago
EHA Library; A. Thompson M. Jun 12 2020; 294884;
Source: library.ehaweb.orgCategories: General Medicine News, Hem/OncsTweet-
Global rates of influenza (FV) & pneumococcal (PV) vax in MM: Impact on HRU & OS [6/12/20] @mtmdphd et al. Abs EP967 #EHA25 https://t.co/lB14KmSH9S #mmsm #IDonc Multivariate analysis - FV & PV significantly impacted OS when adjusted for age, region, and ECOG PS (Table)
-
-
Mashup Score: 1GLOBAL RATES OF INFLUENZA (FV) AND PNEUMOCOCCAL (PV) VACCINATION IN... by Dr. Michael A. Thompson - 1 year(s) ago
EHA Library; A. Thompson M. Jun 12 2020; 294884;
Source: library.ehaweb.orgCategories: General Medicine News, Hem/OncsTweet-
Global rates of influenza (FV) & pneumococcal (PV) vax in MM: Impact on HRU & OS [6/12/20] @mtmdphd et al. Abs EP967 #EHA25 https://t.co/lB14KmSH9S #mmsm #IDonc Multivariate analysis - FV & PV significantly impacted OS when adjusted for age, region, and ECOG PS (Table)
-
-
Mashup Score: 0GLOBAL RATES OF INFLUENZA (FV) AND PNEUMOCOCCAL (PV) VACCINATION IN... by Dr. Michael A. Thompson - 1 year(s) ago
EHA Library; A. Thompson M. Jun 12 2020; 294884;
Source: library.ehaweb.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Global rates of influenza (FV) & pneumococcal (PV) vax in MM: Impact on HRU & OS [6/12/20] @mtmdphd et al. Abs EP967 #EHA25 https://t.co/lB14KmSH9S #mmsm #IDonc Multivariate analysis - FV & PV significantly impacted OS when adjusted for age, region, and ECOG PS (Table)
-
Global rates of influenza (FV) & pneumococcal (PV) vax in MM Pts [6/12/20] @mtmdphd et al. Abs EP967 #EHA25 https://t.co/lB14KmSH9S #mmsm #IDonc n > 2500; 40%, (FV last yr) & 30% PV (prior 5yr) w/ FV: 56%/38%/27%/4% & PV: 43%/28%/21%/5% in US/Europe/Latin America/Asia
-
Global rates of influenza (FV) and pneumococcal (PV) vaccination in multiple myeloma (MM) patients (Pts) in INSIGHT MM: Impact on healthcare resource utilization (HRU) and overall survival (OS) [6/12/20] @mtmdphd et al. Abstract EP967 #EHA25 https://t.co/lB14KmSH9S #mmsm #IDonc https://t.co/My9KLnsYPI
-
-
Mashup Score: 9INFECTIONS FOLLOWING BISPECIFIC ANTIBODIES IN MYELOMA: A SYSTEMATIC... by Edward R Scheffer Cliff - 1 year(s) ago
Access educational materials, eLearning activities, accredited Live webinar sessions with polls and chat on this fast Digital Library and Hybrid Virtual Event Platform powered by MULTILEARNING LMS.
Source: library.ehaweb.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Pleased to share our abstract #EHA2023, w @NCICancer’s Gemma Reynolds; systematic review of infections after bispecific antibodies in myeloma - 56% prevalence of infections, 21% Gr≥3 - approx half bacterial half viral - more w BCMA-BsAb, more w combos https://t.co/2pfEXA60Pp https://t.co/dLMmxmpI7Y
-
-
Mashup Score: 0PRELIMINARY RESULTS OF QUIWI: A DOUBLE BLINDED, RANDOMIZED CLINICAL... by Pau Montesinos - 1 year(s) ago
Access educational materials, eLearning activities, accredited Live webinar sessions with polls and chat on this fast Digital Library and Hybrid Virtual Event Platform powered by MULTILEARNING LMS.
Source: library.ehaweb.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
PRELIMINARY RESULTS OF QUIWI: A DOUBLE BLINDED, RANDOMIZED CLINICAL TRIAL COMPARING STANDARD CHEMOTHERAPY PLUS QUIZARTINIB VERSUS PLACEBO IN ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3-ITD WILD-TYPE AML https://t.co/XnnE9FHzcR #leusm #AML #EHA23 https://t.co/fVei1FgjNo
-
-
Mashup Score: 1FLAG-IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD... by Prof. Nigel Russell - 1 year(s) ago
Access educational materials, eLearning activities, accredited Live webinar sessions with polls and chat on this fast Digital Library and Hybrid Virtual Event Platform powered by MULTILEARNING LMS.
Source: library.ehaweb.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
FLAG-IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD LEVELS AND IMPROVED OVERALL SURVIVAL IN NPM1MUT AML INDEPENDENT OF FLT3 AND MRD STATUS, RESULTS FROM THE AML19 TRIAL https://t.co/0RM6PpVEyO #EHA23 #AML #leusm https://t.co/3cyYhgmvLN
-
-
Mashup Score: 2UPDATED RESULTS OF VEN-A-QUI STUDY: A PHASE 1-2 TRIAL TO ASSESS THE... by Juan Miguel Bergua Burgues - 1 year(s) ago
Access educational materials, eLearning activities, accredited Live webinar sessions with polls and chat on this fast Digital Library and Hybrid Virtual Event Platform powered by MULTILEARNING LMS.
Source: library.ehaweb.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
UPDATED RESULTS OF VEN-A-QUI STUDY: A PHASE 1-2 TRIAL TO ASSESS THE SAFETY AND EFFICACY OF TRIPLETS FOR NEWLY DIAGNOSED UNFIT AML PATIENTS: AZACITIDINE OR LOW-DOSE CYTARABINE WITH VENETOCLAX AND QUIRZATINIB https://t.co/lrgNGIYZpP #EHA23 #AML #leusm https://t.co/6Lnd1nMsEG
-
-
Mashup Score: 0POST-TRANSPLANT NIVOLUMAB PLUS UNSELECTED AUTOLOGOUS LYMPHOCYTES IN... by Dr. Fabio Guolo - 1 year(s) ago
Access educational materials, eLearning activities, accredited Live webinar sessions with polls and chat on this fast Digital Library and Hybrid Virtual Event Platform powered by MULTILEARNING LMS.
Source: library.ehaweb.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
POST-TRANSPLANT NIVOLUMAB PLUS UNSELECTED AUTOLOGOUS LYMPHOCYTES IN REFRACTORY HODGKIN LYMPHOMA RESULTS IN VERY HIGH REMISSION RATE AND EXCELLENT SURVIVAL AND IT IS ASSOCIATED WITH NK CELL EXPANSION #EHA23 #lymsm https://t.co/MiuMa38N0K https://t.co/BIqBdHISXz
-
Molecular Genetic Testing Patterns in Newly Dx AML: CONNECT® Registry [May 18, 2017] @DanPollyea et al. Abstract: E923 #EHA22 https://t.co/NOvxkVe5nr #NCT01688011 #AMLsm #leusm #oncopath #camoldx #PrecisionMedicine https://t.co/NwOTZTzC03